1. Clinical & Scientific Overview
Osimertinib Mesylate (TIP-MED-000570, Reference Code [ONC-21]) is classified under
Oncology & Antineoplastic Medicines as a Targeted Therapy (EGFR TKI) • Third-Generation Mutant-Selective Irreversible EGFR Tyrosine Kinase Inhibitor (TKI).
Within the Indian regulatory and compendial framework, it is governed under Schedule H (Prescription Only — Specialist Oncology Supervision).
Tagrisso (AstraZeneca Pharma India), Osicent (Incepta / Special Access)
Film-Coated Tablet: 40 mg, 80 mg
Oncology Specialisation & Cytotoxic Safety Protocol
Targeted Therapy (EGFR TKI)
Antineoplastic Targeted Agent
Standard Regimen & Cycle Context: 80 mg orally once daily with or without food.
Signature Dose-Limiting Toxicities & Organ Monitoring: Interstitial Lung Disease (ILD) / Pneumonitis (3–4% — withhold immediately for acute dyspnoea/cough/fever and permanently discontinue if confirmed), QTc interval prolongation, LVEF decline/cardiomyopathy (especially in patients with cardiac risk factors), paronychia, diarrhoea, and acneiform rash.
Extravasation, Premedication & Safe Cytotoxic Handling: Confirm EGFR mutation status (Ex19del, L858R, or T790M via tissue NGS or liquid biopsy ctDNA) prior to initiation; perform baseline and periodic ECG (QTc) and 2D-Echo (LVEF).
3. Mechanism of Action & Pharmacodynamics
Forms a covalent bond with the C797 cysteine residue in the ATP-binding pocket of mutated EGFR, potently inhibiting both sensitising EGFR mutations (Exon 19 deletion, L858R) and the acquired T790M gatekeeper resistance mutation while sparing wild-type EGFR, with high blood-brain barrier penetration.
4. Therapeutic Indications & Evidence-Supported Uses
- Adjuvant post-resection and first-line metastatic NSCLC harbouring EGFR Exon 19 deletion or Exon 21 L858R mutations
- Metastatic EGFR T790M mutation-positive NSCLC after prior EGFR TKI
5. Educational Dosage Context, Formulations & Administration
Educational Dosing & Regimen Summary: Educational Oncology Regimen Context (Specialist Reference Only): 80 mg orally once daily with or without food.
Administration & Meal Timing: 80 mg orally once daily with or without food.
6. Pharmacokinetics, Metabolism & Renal/Hepatic Adjustment
Specialist oncology pharmacokinetic profile; dosing depends on Body Surface Area (BSA in m2), Calvert GFR formula, or flat targeted dosing with strict organ-function adjustments.
Hepatic enzymatic activation/inactivation or proteolytic degradation (for monoclonal antibodies); see specific polymorphism and interaction notes.
Verify serum creatinine and eGFR before every cycle; see drug-specific renal dosing and uroprotection rules.
Check total bilirubin, AST, and ALT prior to each cycle; taxanes, anthracyclines, and TKIs require strict hepatic dose modification.
7. Contraindications, Precautions & High-Risk Warnings
- Severe hypersensitivity to Osimertinib or formulation vehicle
- Pregnancy and lactation (potent teratogen/embryotoxic class warning unless explicitly evaluated by oncology specialist)
- Severe unrecovered bone marrow aplasia or decompensated organ failure per protocol thresholds
Key Clinical Precautions: Interstitial Lung Disease (ILD) / Pneumonitis (3–4% — withhold immediately for acute dyspnoea/cough/fever and permanently discontinue if confirmed), QTc interval prolongation, LVEF decline/cardiomyopathy (especially in patients with cardiac risk factors), paronychia, diarrhoea, and acneiform rash.
8. Adverse Effects Profile
- Interstitial Lung Disease (ILD) / Pneumonitis (3–4% — withhold immediately for acute dyspnoea/cough/fever and permanently discontinue if confirmed), QTc interval prolongation, LVEF decline/cardiomyopathy (especially in patients with cardiac risk factors), paronychia, diarrhoea, and acneiform rash.
- Interstitial Lung Disease (ILD) / Pneumonitis (3–4% — withhold immediately for acute dyspnoea/cough/fever and permanently discontinue if confirmed), QTc interval prolongation, LVEF decline/cardiomyopathy (especially in patients with cardiac risk factors), paronychia, diarrhoea, and acneiform rash.
9. Major Drug–Drug, Drug–Food & Drug–Herb Interactions
- Interstitial Lung Disease (ILD) / Pneumonitis (3–4% — withhold immediately for acute dyspnoea/cough/fever and permanently discontinue if confirmed), QTc interval prolongation, LVEF decline/cardiomyopathy (especially in patients with cardiac risk factors), paronychia, diarrhoea, and acneiform rash.
- Avoid live-attenuated vaccines during immunosuppressive chemotherapy; verify CYP3A4, UGT1A1, DPD, and QTc interactions before each cycle.
10. Clinical Monitoring, Patient Counselling & Storage
Clinical & Laboratory Monitoring: Confirm EGFR mutation status (Ex19del, L858R, or T790M via tissue NGS or liquid biopsy ctDNA) prior to initiation; perform baseline and periodic ECG (QTc) and 2D-Echo (LVEF).
Pharmacist Patient Counselling Points:
- Confirm EGFR mutation status (Ex19del, L858R, or T790M via tissue NGS or liquid biopsy ctDNA) prior to initiation; perform baseline and periodic ECG (QTc) and 2D-Echo (LVEF).
- Report fever >=38.0°C (100.4°F) immediately (medical emergency: possible febrile neutropenia).
- Follow strict reproductive contraception and safe cytotoxic oral handling instructions.
Storage, Stability & Dispensing Safeguards: Confirm EGFR mutation status (Ex19del, L858R, or T790M via tissue NGS or liquid biopsy ctDNA) prior to initiation; perform baseline and periodic ECG (QTc) and 2D-Echo (LVEF).
11. Visual Pharmacology & Mechanism Diagram (svg-v339-01-adme-12-step-journey)
12. Authoritative References, Regulatory Sources & Editorial Disclaimer
Primary Compendial & Guideline Reference: National Cancer Grid (NCG) India Consensus Guidelines; NLEM 2022 Antineoplastic Section; Indian Pharmacopoeia (IP) & CDSCO Approved Oncology Prescribing Information.
Official Verification Portals: National Cancer Grid (NCG) India — Evidence-Based Oncology Guidelines • CDSCO — Central Drugs Standard Control Organization Approved Drug Data • Indian Pharmacopoeia Commission (IPC)
Last Medically & Pharmaceutically Reviewed: 2026-11-10 • Verification Status: VERIFIED_EDUCATIONAL_CONTENT
Educational & Clinical Disclaimer: This reference profile is published solely for pharmacy education, academic study, and professional clinical reference. It does not substitute for patient-specific clinical judgement, qualified specialist oncology/medical supervision, or official CDSCO/IP prescribing information. Never self-medicate with prescription, Schedule H/H1/X, NDPS, or oncology medicines.